1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
A new microneedle patch helps repair spinal cord injuries by reducing scarring and promoting nerve growth.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
August 2019 in “Journal of The American Academy of Dermatology” RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
August 2018 in “Journal of The American Academy of Dermatology” Finasteride helps female-pattern hair loss.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
47 citations
,
October 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
32 citations
,
December 2018 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
14 citations
,
January 2020 in “Advances in Dermatology and Allergology” Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.
12 citations
,
February 2025 in “Scientific Reports” MSC-EVs and UCB-EVs improve skin wound healing and reduce scarring.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
2 citations
,
October 2025 in “Discover Immunity.” Alopecia Areata is an autoimmune disease causing hair loss, with no cure yet, but research may lead to new treatments.
2 citations
,
November 2023 in “Frontiers in microbiology” The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
Baricitinib effectively regrows hair in severe alopecia areata cases.
September 2025 in “International Journal of Innovative Technologies in Social Science” Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
June 2025 in “Saratov Medical Journal” Ongoing research and innovation are crucial for improving skin care and treatment.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.